Record Q2 net revenues and active patients drove a 16% year-over-year revenue increase, with all major products contributing and strong international growth. Gross margin improved to 78%, and positive adjusted EBITDA was achieved. Full-year guidance was raised, reflecting commercial momentum and a clear path to profitability.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.